• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Daniel C. Cho, MD


  • Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA.First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.Cancer Discovery. 2013 Apr;3(4):406-17.
  • Zhu S, Cohen MB, Bjorge JD, Mier JW, Cho DC.PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.J Cell Mol Med. 2013 Mar;17(3):377-85.
  • Cho DC, Mier JW.Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma.Curr Cancer Drug Targets. 2013 Feb 1;13(2):126-42.
  • Cho DC.Therapeutic challenges in advanced renal cell carcinoma.Clin Pract (Lond). 2013 Jan;10(1):39-46.
  • Srivastava N, Cho DC.Perifosine in renal cell carcinoma.Expert Opin Investig Drugs. 2013 Feb;22(2):285-91.
  • Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ.Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.Cancer. 2012 Dec 15;118(24):6055-62.
  • Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK.Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.Eur J Cancer. 2012 Jul;48(10):1519-24.
  • Cho DC, Atkins MB.Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?.Clin Cancer Res. 2012 Jun 1;18(11):2999-3001.
  • Battelli C, Cho DC.mTOR inhibitors in renal cell carcinoma.Therapy. 2011 Jul;8(4):359-367.
  • Pandya SS, Mier JW, McDermott DF, Cho DC.Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.BJU Int. 2011 Feb 14.
  • Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S.Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.BJU Int. 2010 Sep;106(6):772-8.
  • Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW.The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.Clin Cancer Res. 2010 Jul 15;16(14):3628-38.
  • Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antr├ás L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.Urol Oncol. 2010 May 5.
  • Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S.Treatment selection for patients with metastatic renal cell carcinoma.Cancer. 2009 May 15;115(10 Suppl):2327-33. Review.
  • Medioni J,Choueiri TK,Zinzindohoue F,Cho D,Fournier L,Oudard S.Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.J Urol. 2009 Jun;181(6):2470-5; discussion 2475.
  • Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF.Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.J Immunother. 2009 Feb-Mar;32(2):181-5.
  • Lee HJ, Cho DY, Park JC, Bae SB, Lee KT, Cho IS, Han CS, Park SY, Yun HJ, Kim S.Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.Cancer Chemother Pharmacol. 2009 Feb;63(3):427-32.
  • Song H, Park G, Kim YS, Hur I, Kim H, Ryu JW, Lee HK, Cho DH, Choi IH, Lee WJ, Hur DY.B7-H4 reverse signaling induces the apoptosis of EBV-transformed B cells through Fas ligand up-regulation.Cancer Lett. 2008 Aug 8;266(2):227-37.
  • Cho DS, Yim H, Cho KS, Hong SJ, Cho NH, Kim SI, Ahn HS, Kim SJ.Impact of caveolin-1 expression on the prognosis of transitional cell carcinoma of the upper urinary tract.J Korean Med Sci. 2008 Apr;23(2):296-301.
  • Jung C, Yim SC, Cho DY, Chang HN, Park HG.Microarray-based detection of Korean-specific BRCA1 mutations.Anal Bioanal Chem. 2008 May;391(1):405-13.
  • Goh DH, Lee SH, Cho DC, Park SH, Hwang JH, Sung JK.Chronic idiopathic myelofibrosis presenting as cauda equina compression due to extramedullary hematopoiesis: a case report.J Korean Med Sci. 2007 Dec;22(6):1090-3.
  • Panka DJ, Cho DC, Atkins MB, Mier JW.GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.J Biol Chem. 2008 Jan 11;283(2):726-32.
  • Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.Clin Genitourin Cancer. 2007 Sep;5(6):379-85.
  • Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. Review.
  • Cho D, Panka P, Panka D, Atkins MB, Mier JW.Sensitivity of renal cell carcinoma (RCC) cell lines to Sorafenib in vitro is dependent upon Akt and GSK3▀ activity.J Am Diet Assoc. 2006 SEP 01;2006:4515.
  • Cho D, McDermott D, Atkins M.Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools.Curr Urol Rep. 2006 Jan;7(1):8-15.
  • Cho D, Atkins MB, Mier JW.Inhibition of glycogen synthase 3b (GSK3b) enhances the in vitro activity of the Akt inhibitor perifosine in renal cell carcinoma (RCC) cell lines.J Am Diet Assoc. 2007:1823.
  • Cho D, McDermott D, Atkins M.Designing Clinical Trials for Kidney Cancer Based on Newly Developed Prognostic and Predictive Tools.Current Urology Reports. 2006 JAN 01;7(1).
  • Cho D, Aktins MB.Molecular aberrations in kidney cancer: vertical and horizontal inhibition of signaling pathways.J Am Diet Assoc. 2005 Dec 30;1(1):5-8.